First Artificial Intelligence (AI) Device Approved by US FDA for Diabetic Retinopathy

The US Food and Drug Administration (FDA) for the first time has approved an Artificial Intelligence (AI) device that can help detect certain types of diabetes-related eye diseases.

First Artificial Intelligence (AI)-based device to detect certain diabetes-related eye problems has been approved by the US Food and Drug Administration (FDA).

The device, called IDx-DR, is a software programme that uses an artificial intelligence algorithm to analyse images of the eye taken with a retinal camera.

Broccoli-related Compound Yields Possible Treatment for Eye Disease
I3C compound in broccoli helps activate the aryl hydrocarbon receptor protein which involves in chemical detoxification but declines with aging.

‘US FDA for the first time has given a thumps up for an Artificial Intelligence (AI)device that can detect diabetes-related eye diseases.’

The FDA permitted marketing of IDx-DR to Iowa-based medical device company IDx LLC on Wednesday to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.

Diabetic retinopathy, a common cause of vision loss among people living with diabetes, occurs when high levels of blood sugar lead to damage in the blood vessels of the retina, the light-sensitive tissue in the back of the eye.

"Early detection of retinopathy is an important part of managing care for the millions of people with diabetes, yet many patients with diabetes are not adequately screened for diabetic retinopathy since about 50 percent of them do not see their eye doctor on a yearly basis," Malvina Eydelman of FDA's Center for Devices and Radiological Health said in a statement.

Diabetic Retinopathy - Risk Factors - Symptoms - Treatment - Diagnosis - FAQs
The term ‘diabetic retinopathy’ refers to changes in the retina which often occur in people with diabetes.

"Today's decision permits the marketing of a novel artificial intelligence technology that can be used in a primary care doctor's office," Eydelman said.

IDx-DR provides a screening decision without the need for a clinician to also interpret the image or results, which makes it usable by health care providers who may not normally be involved in eye care.

Two Key Players Produce Destructive Cascade of Diabetic Retinopathy
During diabetes the retina can be bombarded by reactive oxygen species, prompting events that destroy healthy blood vessels, form leaky new ones and ruin vision.

A doctor uploads the digital images of the patient's retinas to a Cloud server on which IDx-DR software is installed.

If the images are of sufficient quality, the software provides the doctor with one of two results, either "more than mild diabetic retinopathy detected: refer to an eye care professional" or "negative for more than mild diabetic retinopathy: re-screen in 12 months."

Eye Fat Could Help Prevent Diabetic Retinopathy
A particular type of lipid or fat present in eyes may play a key role in deterring the eye disease diabetic retinopathy, revealed researchers.

If a positive result is detected, patients should see an eye care provider for further diagnostic evaluation and possible treatment as soon as possible.

The FDA evaluated data from a clinical study of retinal images obtained from 900 patients with diabetes at 10 primary care sites.

In the study, IDx-DR was able to correctly identify the presence of more than mild diabetic retinopathy 87.4 per cent of the time and was able to correctly identify those patients who did not have more than mild diabetic retinopathy 89.5 per cent of the time, FDA said.

The FDA, however, said that IDx-DR should not be used in patients with diabetes who are pregnant as diabetic retinopathy can progress very rapidly during pregnancy and the device is not intended to evaluate rapidly progressive diabetic retinopathy.

Source-IANS